PARADIGM-HF — The Experts’ Discussion

By this time, you have heard about the PARADIGM-HF trial, which studied the use of LCZ696, a novel molecule combining a neprilysin inhibitor (sacubitril) with an angiotension receptor blocker (valsartan). Play the video below (courtesy of YouTube and NEJM) to see an expert panel discussion with Dr. Milton Packer (Professor & Chairman of the Department of Clinical Science, at UTSW), one of the primary investigators in this trial. In the discussion, Dr. Packer, along with co-chair Dr. John J.V. McMurray (Professor of Cardiology at the University of Glasgow) discuss the basis/rationale behind neprilysin inhibition, trial design, trial results, and adverse events.